**Chapter 13**

[18] Nambara S, Masuda T, Nishio M,

*Ovarian Cancer - Updates in Tumour Biology and Therapeutics*

et al. Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. Oncotarget

2017; 8(64): 107666–107677.

Med 2014; 6(10): 1263–1278.

2020; 11: 661–694.

1122–1133.

**234**

[20] Slade L, Pulinilkunnil T. The MiTF/ TFE family of transcription tactors: master regulators of organelle signaling, metabolism, and stress adaptation. Mol Cancer Res 2017; 15(12):1637–1643.

[21] Li N, Li H, Wang Y, Cao L, Zhan X. Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine. EPMA J

[22] Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Lasseter KC. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002; 42(10):

[23] Li N, Zhan X, Zhan X. The lncRNA SNHG3 regulates energy metabolism of

ovarian cancer by an analysis of mitochondrial proteomes. Gynecol

Oncol. 2018; 150: 343–354.

[19] Melotti A, Mas C, Kuciak M, Lorente-Trigos A, Borges I, Ruiz i Altaba A. The river blindness drug ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol
